A detailed history of Ci Investments Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Ci Investments Inc. holds 3,355 shares of HALO stock, worth $157,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,355
Previous 3,447 2.67%
Holding current value
$157,550
Previous $180,000 6.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$51.3 - $64.42 $4,719 - $5,926
-92 Reduced 2.67%
3,355 $192,000
Q2 2024

Aug 12, 2024

SELL
$37.81 - $52.4 $7,297 - $10,113
-193 Reduced 5.3%
3,447 $180,000
Q1 2024

May 13, 2024

BUY
$33.68 - $41.95 $54,763 - $68,210
1,626 Added 80.73%
3,640 $148,000
Q4 2023

Feb 12, 2024

SELL
$33.32 - $42.1 $145,308 - $183,598
-4,361 Reduced 68.41%
2,014 $74,000
Q3 2023

Nov 13, 2023

SELL
$36.46 - $44.03 $187,987 - $227,018
-5,156 Reduced 44.71%
6,375 $244,000
Q2 2023

Aug 11, 2023

BUY
$30.28 - $38.74 $81,180 - $103,861
2,681 Added 30.29%
11,531 $416,000
Q1 2023

May 12, 2023

BUY
$32.86 - $55.7 $42,586 - $72,187
1,296 Added 17.16%
8,850 $338,000
Q4 2022

Feb 10, 2023

BUY
$40.06 - $59.44 $294,441 - $436,884
7,350 Added 3602.94%
7,554 $430,000
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $7,860 - $10,563
204 New
204 $8,000
Q1 2021

May 13, 2021

SELL
$39.51 - $51.45 $519,279 - $676,207
-13,143 Closed
0 $0
Q4 2020

Feb 09, 2021

BUY
$25.81 - $43.62 $339,220 - $573,297
13,143 New
13,143 $561,000
Q3 2020

Nov 09, 2020

SELL
$25.74 - $29.63 $299,690 - $344,982
-11,643 Closed
0 $0
Q2 2020

Aug 07, 2020

BUY
$16.25 - $26.81 $189,198 - $312,148
11,643 New
11,643 $312,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.54B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Ci Investments Inc. Portfolio

Follow Ci Investments Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ci Investments Inc. with notifications on news.